Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 7,682

Sort by:

Drug Discovery Outsourcing (DDO) Global Market – Forecast To 2030 US$ 7,200.00

... all segments, global trends and emerging strategies of the outsourcing market related to drug discovery. Major Drug Discovery Outsourcing (DDO) players included in the report are Evotec, Charles ...

May 2021 238 pages

North America: Vitamins Market US$ 1,999.00

... report on the vitamins market in North America covers the following countries: Canada, Mexico, and the United States of America. The report on the vitamins market in North America includes: Analysis and ...

May 2021 150 pages

Global Antibiotics Partnering Terms and Agreements 2010 to 2021 US$ 3,495.00

... healthcare sectors, covering: Antibiotics Aminoglycosides Cephalosporin Clindamycin Macrolides Penicillin Quinolones Sulfonamides Tetracycline Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into ...

May 2021 300 pages

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drugs in Development, 2021 US$ 3,000.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development ...

April 2021 60 pages

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Drugs in Development, 2021 US$ 3,000.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) development ...

April 2021 35 pages

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drugs in Development, 2021 US$ 3,000.00

... and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and ...

April 2021 75 pages

Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) - Drugs in Development, 2021 US$ 3,000.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10A (Death Receptor 4 or TNF Related Apoptosis Inducing Ligand Receptor 1 or TRAIL Receptor 1 or DR4 or CD261 or TNFRSF10A) development ...

April 2021 45 pages

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drugs in Development, 2021 US$ 3,000.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development ...

April 2021 65 pages

1 Phosphatidylinositol 3 Phosphate 5 Kinase (FYVE Finger Containing Phosphoinositide Kinase or Phosphatidylinositol 3 Phosphate 5 Kinase Type III or PIKFYVE or EC 2.7.1.150) - Drugs in Development, 2021 US$ 3,000.00

April 2021 35 pages

1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 US$ 3,000.00

1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 SUMMARY 1,3 Beta Glucan Synthase (EC 2.4.1.34) - Drugs in Development, 2021 provides in depth analysis on 1,3 Beta Glucan Synthase (...

April 2021 30 pages

16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 US$ 3,000.00

16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 SUMMARY 16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 provides in depth analysis on 16S Ribosomal RNA (16S rRNA) targeted pipeline...

April 2021 85 pages

23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 US$ 3,000.00

23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 SUMMARY 23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 provides in depth analysis on 23S Ribosomal RNA (23S rRNA) targeted pipeline...

April 2021 70 pages

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) - Drugs in Development, 2021 US$ 3,000.00

3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) - Drugs in Development, 2021 SUMMARY 3 Hydroxy 3 Methylglutaryl Coenz...

April 2021 80 pages

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) - Drugs in Development, 2021 US$ 3,000.00

3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 (5 Alpha SR2 or Steroid 5 Alpha Reductase 2 or Type II 5 Alpha Reductase or SR Type 2 or SRD5A2 or EC 1.3.1.22) - Drugs in Development, 2021 SUMMARY 3-Oxo 5-Alp...

April 2021 35 pages

30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 US$ 3,000.00

30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 SUMMARY 30S Ribosomal Subunit (30S RNA) - Drugs in Development, 2021 provides in depth analysis on 30S Ribosomal Subunit (30S RNA) targeted...

April 2021 40 pages

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 US$ 3,000.00

3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 SUMMARY 3C Like Proteinase (3CL-PRO or 3CLp or EC 3.4.22.) - Drugs in Development, 2021 provides in depth analysis on 3C...

April 2021 60 pages

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1...

April 2021 115 pages

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or Serotonin 1D Beta Receptor or Serotonin Receptor 1B or HTR1B) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1B (5 HT1B or S12 or S...

April 2021 55 pages

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D Alpha Receptor or Serotonin Receptor 1D or HTR1D) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 1D (5 HT1D or Serotonin 1D A...

April 2021 60 pages

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) - Drugs in Development, 2021 provides in depth anal...

April 2021 45 pages

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) - Drugs in De...

April 2021 170 pages

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxytryptamine Receptor 1C or Serotonin Receptor 2C or HTR2C) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 2C (5 HT2C or 5 Hydroxyt...

April 2021 50 pages

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) - Drugs in Development, 2021 provid...

April 2021 60 pages

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) - Drugs in Developmen...

April 2021 40 pages

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Development, 2021 US$ 3,000.00

5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Development, 2021 SUMMARY 5-Hydroxytryptamine Receptor (Serotonin Receptor or 5 HT Receptor or HTR) - Drugs in Deve...

April 2021 40 pages

50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 US$ 3,000.00

50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 SUMMARY 50S Ribosomal Subunit (50S RNA) - Drugs in Development, 2021 provides in depth analysis on 50S Ribosomal Subunit (50S RNA) targeted...

April 2021 30 pages

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 US$ 3,000.00

70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY 70 kDa Ribosomal Protein S6 Kinase (p70S6K or EC 2.7.11.1) - Drugs in Development, 2021 provides in dept...

April 2021 35 pages

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drugs in Development, 2021 US$ 3,000.00

April 2021 30 pages

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drugs in Development, 2021 US$ 3,000.00

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drugs in Development, 2021 SUMMARY Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)...

April 2021 30 pages

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in Development, 2021 US$ 3,000.00

Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in Development, 2021 SUMMARY Acetyl CoA Carboxylase (Acetyl Coenzyme A Carboxylase or ACC or EC 6.4.1.2) - Drugs in...

April 2021 30 pages

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) - Drugs in Development, 2021 US$ 3,000.00

Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) - Drugs in Development, 2021 SUMMARY Acetylcholinesterase (Acetylcholin...

April 2021 105 pages

Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 US$ 2,000.00

Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Achromatopsia (Genetic Disorders) - Drugs in Development, 2021 provides an overview of the Achromatopsia pipeline landscape. The...

April 2021 30 pages

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type A (Genetic Disorder...

April 2021 35 pages

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type B (Genetic Disorder...

April 2021 35 pages

Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 SUMMARY Acquired (Autoimmune) Hemolytic Anemia (Hematological Disorders) - Drugs in Development, 2021 prov...

April 2021 50 pages

Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 SUMMARY Acral Lentiginous Melanoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acral Lentiginous Melanoma pip...

April 2021 30 pages

Acute Bronchitis (Respiratory) - Drugs in Development, 2021 US$ 2,000.00

Acute Bronchitis (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Bronchitis (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Bronchitis pipeline landscape. The rep...

April 2021 30 pages

Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 US$ 2,000.00

Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 SUMMARY Acute Coronary Syndrome (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Acute Coronary Syndrome...

April 2021 50 pages

Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 US$ 2,000.00

Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 SUMMARY Acute Heart Failure (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Acute Heart Failure pipeline lan...

April 2021 50 pages

Acute Inflammation (Immunology) - Drugs in Development, 2021 US$ 2,000.00

Acute Inflammation (Immunology) - Drugs in Development, 2021 SUMMARY Acute Inflammation (Immunology) - Drugs in Development, 2021 provides an overview of the Acute Inflammation pipeline landscape. The...

April 2021 45 pages

Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 US$ 2,000.00

Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 SUMMARY Acute Ischemic Stroke (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Acute Ischem...

April 2021 125 pages

Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 US$ 2,000.00

Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Acute Liver Failure (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Acute Liver Failure pipeline...

April 2021 45 pages

Acute Lung Injury (Respiratory) - Drugs in Development, 2021 US$ 2,000.00

Acute Lung Injury (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Lung Injury (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Lung Injury pipeline landscape. The...

April 2021 115 pages

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Lymphoblastic Lympho...

April 2021 45 pages

Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 US$ 2,000.00

Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 SUMMARY Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 provides an overview of the Acute Opioid Overdosage pipeline...

April 2021 40 pages

Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 US$ 2,000.00

Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the Acute Promyelocytic Leukem...

April 2021 35 pages

Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 US$ 2,000.00

Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Respiratory Failure...

April 2021 30 pages

Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 US$ 2,000.00

Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 SUMMARY Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 provides an...

April 2021 45 pages

Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 US$ 2,000.00

Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 SUMMARY Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Acute...

April 2021 35 pages

Addiction (Central Nervous System) - Drugs in Development, 2021 US$ 2,000.00

Addiction (Central Nervous System) - Drugs in Development, 2021 SUMMARY Addiction (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Addiction pipeline landscape. The re...

April 2021 45 pages

Filters

Clear all